Rho-kinase inhibitor Y-27632 attenuates pulmonary hypertension in hyperoxia-exposed newborn rats

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aim: To test the hypothesis that neonatal hyperoxia induced pulmonary hypertension accompanied by increased Rho-kinase expression in rat lungs and that Rho-kinase inhibitor could attenuate right ventricular hypertrophy and pulmonary arterial remodeling. Methods: Newborn rats were exposed to >95% O 2 in the first week after birth, then to 60% O 2 in the following 2 weeks. Control pups were exposed to room air over the same periods. The pups were injected with either Rho-kinase inhibitor Y-27632 (10 mg·kg-1 ·d -1, ip) or vehicle from postnatal d 14 to 20. Lung and heart tissues were collected on postnatal d 7 and 21. Rho-kinase activity in lungs was measured using Western blotting and immunohistochemistry. The right ventricular hypertrophy and arterial medial wall thickness (MWT) were assessed morphologically. Results: Rho-kinase activity in lungs was comparable between the hyperoxic and control pups on postnatal d 7, but it had a more than 2-fold increase in the hyperoxic pups on postnatal d 21. Moreover, the hyperoxic exposure induced structural features of pulmonary hypertension, as shown by the right ventricular hypertrophy and significantly increased arterial MWT. Administration with Y-27632 effectively blocked the hyperoxia-induced increase of Rho-kinase activity in lungs, and attenuated the right ventricular hypertrophy. Conclusion: Rho-kinase inhibitor may be a novel therapy for attenuating the hyperoxia-induced structural changes in pulmonary hypertension.

Original languageEnglish
Pages (from-to)1310-1316
Number of pages7
JournalActa Pharmacologica Sinica
Volume34
Issue number10
DOIs
Publication statusPublished - Oct 2013

Fingerprint

rho-Associated Kinases
Hyperoxia
Pulmonary Hypertension
Right Ventricular Hypertrophy
Lung
Y 27632
Western Blotting
Immunohistochemistry
Air
Parturition

Keywords

  • Hyperoxia
  • Lung injury
  • Neonate
  • Pulmonary hypertension
  • Rho-kinase
  • Y-27632

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Rho-kinase inhibitor Y-27632 attenuates pulmonary hypertension in hyperoxia-exposed newborn rats. / Chou, Hsiu Chu; Huang, Liang Ti; Yeh, Tsu Fu; Chen, Chung Ming.

In: Acta Pharmacologica Sinica, Vol. 34, No. 10, 10.2013, p. 1310-1316.

Research output: Contribution to journalArticle

@article{cffa3635f7b448f29afd980da49dbf44,
title = "Rho-kinase inhibitor Y-27632 attenuates pulmonary hypertension in hyperoxia-exposed newborn rats",
abstract = "Aim: To test the hypothesis that neonatal hyperoxia induced pulmonary hypertension accompanied by increased Rho-kinase expression in rat lungs and that Rho-kinase inhibitor could attenuate right ventricular hypertrophy and pulmonary arterial remodeling. Methods: Newborn rats were exposed to >95{\%} O 2 in the first week after birth, then to 60{\%} O 2 in the following 2 weeks. Control pups were exposed to room air over the same periods. The pups were injected with either Rho-kinase inhibitor Y-27632 (10 mg·kg-1 ·d -1, ip) or vehicle from postnatal d 14 to 20. Lung and heart tissues were collected on postnatal d 7 and 21. Rho-kinase activity in lungs was measured using Western blotting and immunohistochemistry. The right ventricular hypertrophy and arterial medial wall thickness (MWT) were assessed morphologically. Results: Rho-kinase activity in lungs was comparable between the hyperoxic and control pups on postnatal d 7, but it had a more than 2-fold increase in the hyperoxic pups on postnatal d 21. Moreover, the hyperoxic exposure induced structural features of pulmonary hypertension, as shown by the right ventricular hypertrophy and significantly increased arterial MWT. Administration with Y-27632 effectively blocked the hyperoxia-induced increase of Rho-kinase activity in lungs, and attenuated the right ventricular hypertrophy. Conclusion: Rho-kinase inhibitor may be a novel therapy for attenuating the hyperoxia-induced structural changes in pulmonary hypertension.",
keywords = "Hyperoxia, Lung injury, Neonate, Pulmonary hypertension, Rho-kinase, Y-27632",
author = "Chou, {Hsiu Chu} and Huang, {Liang Ti} and Yeh, {Tsu Fu} and Chen, {Chung Ming}",
year = "2013",
month = "10",
doi = "10.1038/aps.2013.93",
language = "English",
volume = "34",
pages = "1310--1316",
journal = "Acta Pharmacologica Sinica",
issn = "1671-4083",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Rho-kinase inhibitor Y-27632 attenuates pulmonary hypertension in hyperoxia-exposed newborn rats

AU - Chou, Hsiu Chu

AU - Huang, Liang Ti

AU - Yeh, Tsu Fu

AU - Chen, Chung Ming

PY - 2013/10

Y1 - 2013/10

N2 - Aim: To test the hypothesis that neonatal hyperoxia induced pulmonary hypertension accompanied by increased Rho-kinase expression in rat lungs and that Rho-kinase inhibitor could attenuate right ventricular hypertrophy and pulmonary arterial remodeling. Methods: Newborn rats were exposed to >95% O 2 in the first week after birth, then to 60% O 2 in the following 2 weeks. Control pups were exposed to room air over the same periods. The pups were injected with either Rho-kinase inhibitor Y-27632 (10 mg·kg-1 ·d -1, ip) or vehicle from postnatal d 14 to 20. Lung and heart tissues were collected on postnatal d 7 and 21. Rho-kinase activity in lungs was measured using Western blotting and immunohistochemistry. The right ventricular hypertrophy and arterial medial wall thickness (MWT) were assessed morphologically. Results: Rho-kinase activity in lungs was comparable between the hyperoxic and control pups on postnatal d 7, but it had a more than 2-fold increase in the hyperoxic pups on postnatal d 21. Moreover, the hyperoxic exposure induced structural features of pulmonary hypertension, as shown by the right ventricular hypertrophy and significantly increased arterial MWT. Administration with Y-27632 effectively blocked the hyperoxia-induced increase of Rho-kinase activity in lungs, and attenuated the right ventricular hypertrophy. Conclusion: Rho-kinase inhibitor may be a novel therapy for attenuating the hyperoxia-induced structural changes in pulmonary hypertension.

AB - Aim: To test the hypothesis that neonatal hyperoxia induced pulmonary hypertension accompanied by increased Rho-kinase expression in rat lungs and that Rho-kinase inhibitor could attenuate right ventricular hypertrophy and pulmonary arterial remodeling. Methods: Newborn rats were exposed to >95% O 2 in the first week after birth, then to 60% O 2 in the following 2 weeks. Control pups were exposed to room air over the same periods. The pups were injected with either Rho-kinase inhibitor Y-27632 (10 mg·kg-1 ·d -1, ip) or vehicle from postnatal d 14 to 20. Lung and heart tissues were collected on postnatal d 7 and 21. Rho-kinase activity in lungs was measured using Western blotting and immunohistochemistry. The right ventricular hypertrophy and arterial medial wall thickness (MWT) were assessed morphologically. Results: Rho-kinase activity in lungs was comparable between the hyperoxic and control pups on postnatal d 7, but it had a more than 2-fold increase in the hyperoxic pups on postnatal d 21. Moreover, the hyperoxic exposure induced structural features of pulmonary hypertension, as shown by the right ventricular hypertrophy and significantly increased arterial MWT. Administration with Y-27632 effectively blocked the hyperoxia-induced increase of Rho-kinase activity in lungs, and attenuated the right ventricular hypertrophy. Conclusion: Rho-kinase inhibitor may be a novel therapy for attenuating the hyperoxia-induced structural changes in pulmonary hypertension.

KW - Hyperoxia

KW - Lung injury

KW - Neonate

KW - Pulmonary hypertension

KW - Rho-kinase

KW - Y-27632

UR - http://www.scopus.com/inward/record.url?scp=84887395657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887395657&partnerID=8YFLogxK

U2 - 10.1038/aps.2013.93

DO - 10.1038/aps.2013.93

M3 - Article

C2 - 23974518

AN - SCOPUS:84887395657

VL - 34

SP - 1310

EP - 1316

JO - Acta Pharmacologica Sinica

JF - Acta Pharmacologica Sinica

SN - 1671-4083

IS - 10

ER -